Get the Stockscreener App
2.71
1.88%
0.05
After Hours:
2.65
-0.06
-2.21%
Quantum Biopharma Ltd stock is traded at $2.71, with a volume of 107.39K.
It is up +1.88% in the last 24 hours and down -21.68% over the past month.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
See More
Previous Close:
$2.66
Open:
$2.65
24h Volume:
107.39K
Relative Volume:
0.58
Market Cap:
$21.92M
Revenue:
Net Income/Loss:
$-31.97M
P/E Ratio:
-0.328
EPS:
-8.2612
Net Cash Flow:
$-5.66M
1W Performance:
-12.86%
1M Performance:
-21.68%
6M Performance:
-11.73%
1Y Performance:
-64.22%
1-Day Range:
$2.60
$2.74
1-Week Range:
$2.60
$3.1101
52-Week Range:
$2.07
$14.85
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
2.71 | 21.92M | 0 | -31.97M | -5.66M | -8.2612 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Quantum Biopharma Ltd Stock (QNTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-26 | Initiated | Rodman & Renshaw | Buy |
Quantum Biopharma Ltd Stock (QNTM) Latest News
Gross profit of Quantum Biopharma Ltd. Subordinate Voting Shares Class B – HAN:0K91 - TradingView
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis - GlobeNewswire Inc.
A passive investor reports 4.95% ownership of Quantum Biopharma (QNTM). - stocktitan.net
Free float of Quantum Biopharma Ltd. Subordinate Voting Shares Class B – HAN:0K91 - TradingView
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Cash Flow – HAN:0K91 - TradingView
After tax other income/expense of Quantum Biopharma Ltd. Subordinate Voting Shares Class B – HAN:0K91 - TradingView
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Actuals & Estimates (HAN:0K91) - TradingView
Cash runway to 2028 comes with fresh dilution at Quantum BioPharma (QNTM) - Stock Titan
Nearly 2.9 million people have MS. A drug candidate targeting nerve coating gets FDA trial clearance. - Stock Titan
Quantum BioPharma (QNTM.CN) Receives FDA Clearance for Historic Phase 2 Trial of Lucid-MS in Multiple Sclerosis - kalkine.ca
Quantum BioPharma Ltd.: Financial Data Forecasts Estimates and Expectations | QNTM | CA74764Y2050 - marketscreener.com
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance - The Chronicle-Journal
Quantum BioPharma receives FDA clearance for MS phase 2 trial By Investing.com - Investing.com Australia
Quantum BioPharma receives FDA clearance for MS phase 2 trial By Investing.com - Investing.com Canada
Quantum BioPharma receives FDA clearance for MS phase 2 trial By Investing.com - Investing.com India
Quantum BioPharma receives FDA clearance for MS phase 2 trial - Investing.com
Quantum BioPharma receives FDA clearance for MS phase 2 trial By Investing.com - Investing.com UK
Quantum BioPharma Ltd. Receives FDA Clearance To Begin Phase 2 Trial Of Lucid-MS For Multiple Sclerosis - marketscreener.com
Quantum BioPharma receives FDA clearance for MS phase 2 trial By Investing.com - Investing.com Nigeria
Quantum Biopharma amends Form 6-K to add exhibit to F-3 registration statement - Bitget
Quantum Biopharma (QNTM) folds April 2 press release into shelf filing - Stock Titan
April press release now tied to Quantum Biopharma (QNTM) securities registration - Stock Titan
March 30 release now part of Quantum Biopharma (QNTM) registration - Stock Titan
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach - Almaguin News
Why Did Quantum BioPharma (CN:TCM) Stock Surge 6.846% on 4 September 2026? - kalkine.ca
FDA Clears Quantum BioPharma’s Lucid-MS Phase 2 Trial — Could QNTM Be Entering a Pivotal Clinical Chapter? - kalkine.ca
Quantum BioPharma Stock Slides 5.75%: Is Clinical Execution Risk Weighing on QNTM Sentiment? - kalkine.ca
Quantum BioPharma Stock Slides 5.75% as CN:QNTM Delisting Plans Add Fresh Pressure to QNTM Sentiment - kalkine.ca
2026-0904DelistQuantum BioPharma Ltd. (QNTM) - The Canadian Securities Exchange (CSE)
Giving up one stock exchange but not Nasdaq, Quantum BioPharma (NASDAQ: QNTM) reshapes where its shares trade - Stock Titan
Quantum BioPharma to Delist Class B Shares from Canadian Securities Exchange - marketscreener.com
Quantum BioPharma to Delist Class B Shares from Canadian Securities Exchange - Yahoo Finance
Quantum BioPharma Ltd. Applies for Voluntary Delisting of Class B Shares from Canadian Securities Exchange - Quiver Quantitative
Quantum BioPharma to Voluntarily Delist Class B Shares from CSE, Consolidating Trading on Nasdaq - kalkine.ca
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange - Yahoo Finance
QNTM Initiated Coverage by Rodman & Renshaw -- Price Target Set at $8.00 - GuruFocus
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential - TradingView
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential - Benzinga
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential - The Globe and Mail
Quantum BioPharma stock initiated with buy rating at Rodman & Renshaw - Investing.com Nigeria
Quantum BioPharma Ltd. (CN:QNTM) Rises 3.07% as FDA-Cleared Lucid-MS Program Strengthens Investor Optimism - kalkine.ca
Quantum BioPharma stock initiated with buy rating at Rodman & Renshaw - Investing.com
QNTM Stock Analysis: Price-to-Sales Signals Market Skepticism De - GuruFocus
Quantum BioPharma stock initiated with buy rating at Rodman & Renshaw - Investing.com India
Quantum BioPharma Shares Slip 4.44% as Clinical Risk and Biotech Volatility Temper Sentiment - kalkine.ca
Quantum BioPharma Stock Faces Renewed Pressure as Clinical Execution Risk Tests Investor Confidence - kalkine.ca
Headline: Quantum BioPharma Stock Under Pressure After August 25 Decline — Can Lucid-MS Catalyze a Recovery? - kalkine.ca
Quantum BioPharma Falls 4.26% After FDA Clearance Rally: Profit-Taking or a Deeper Signal? - kalkine.ca
Quantum BioPharma Stock Under Pressure as Volatility and Clinical Execution Risks Weigh on Investor Sentiment - kalkine.ca
Quantum (QNTM) Technicals: Trades in a Narrow Directional Range at $3.44 at the Close; the $3.27 to $3.61 Range Remains in Focus in the Latest SessionAdvance Decline Volume - vinanet.vn
Quantum Biopharma Ltd Stock (QNTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):